Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
[Qihuang Jianpi Zishen Granule ameliorates renal injury in patients with systemic lupus erythematosus by regulating immunometabolic reprogramming of macrophages].
СтатьяРандомизированное исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qian Ai, Huang Chuanbing, Zhu Yawen, Hu Kexin, Song Xinran, Xu Yuxiang
Аннотация
OBJECTIVES: To investigate the mechanism of Qihuang Jianpi Zishen Granule (QJZG) for regulating macrophage polarization in renal damage in patients with systemic lupus erythematosus (SLE).
METHODS: Public databases were used to screen the targets of QJZG, SLE and renal damage. An active ingredient-target network and a protein-protein interaction network were constructed followed by molecular docking. Sixty-two SLE patients were randomized into QJZG treatment group and control group (n=31), with 30 healthy individuals as the normal control group. Macrophage polarization markers (iNOS and Arg-1) and AMPK/ULK1 pathway molecules were detected using Western blotting and RT-qPCR, and the changes in renal function, immune indicators, and TCM syndrome scores of the participants were evaluated.
RESULTS: Three key active ingredients of QJZG (quercetin, kaempferol, and 7-O-methylisoflavanone) and 9 core targets were identified, and the target genes were enriched in the TNF, HIF-1, and mTOR pathways. Molecular docking showed strong binding of the active compounds of QJZG with HIF-1α and mTOR. In SLE patients, QJZG treatment significantly improved their renal function, regulated the immune function (increasing CD4+/CD8+ ratio and reducing CD8+ T cells), and reduced TCM syndrome scores. QJZG treatment also significantly downregulated iNOS, mTOR, and HIF-1α expressions and upregulated Arg-1, AMPK, and ULK1 expression in SLE patients.
CONCLUSIONS: QJZG alleviated renal damage in SLE patients through a mechanism involving multiple components and targets. The active ingredients of QJZG regulate macrophage polarization possibly by activating the AMPK/ULK1 pathway via binding to their targets including HIF-1α and mTOR.
METHODS: Public databases were used to screen the targets of QJZG, SLE and renal damage. An active ingredient-target network and a protein-protein interaction network were constructed followed by molecular docking. Sixty-two SLE patients were randomized into QJZG treatment group and control group (n=31), with 30 healthy individuals as the normal control group. Macrophage polarization markers (iNOS and Arg-1) and AMPK/ULK1 pathway molecules were detected using Western blotting and RT-qPCR, and the changes in renal function, immune indicators, and TCM syndrome scores of the participants were evaluated.
RESULTS: Three key active ingredients of QJZG (quercetin, kaempferol, and 7-O-methylisoflavanone) and 9 core targets were identified, and the target genes were enriched in the TNF, HIF-1, and mTOR pathways. Molecular docking showed strong binding of the active compounds of QJZG with HIF-1α and mTOR. In SLE patients, QJZG treatment significantly improved their renal function, regulated the immune function (increasing CD4+/CD8+ ratio and reducing CD8+ T cells), and reduced TCM syndrome scores. QJZG treatment also significantly downregulated iNOS, mTOR, and HIF-1α expressions and upregulated Arg-1, AMPK, and ULK1 expression in SLE patients.
CONCLUSIONS: QJZG alleviated renal damage in SLE patients through a mechanism involving multiple components and targets. The active ingredients of QJZG regulate macrophage polarization possibly by activating the AMPK/ULK1 pathway via binding to their targets including HIF-1α and mTOR.